Syn­cona-backed biotech launch­es in bid to shield heart cells from heart at­tacks

There have not been too many biotechs ex­plic­it­ly fo­cused on car­di­ol­o­gy.

While many have at least made some ef­fort in the space, it is nor­mal­ly not as big of a fo­cus as on­col­o­gy, vac­cines or gene ther­a­py giv­en the large in­vest­ments tra­di­tion­al­ly re­quired to run late-stage tri­als. But that could be chang­ing: Af­ter the launch of UK biotech Kyt­taro fo­cus­ing sole­ly on car­di­ol­o­gy ear­li­er in April, an­oth­er biotech has set up shop in the British Isles.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.